Spark Plug Pipe

Uveitis refers to inflammation caused in the uvea of the eye. A uvea is the middle layer of the eye that consists of three components namely iris, cilliary body, and the choroid. Uveitis is caused by various factors such as inflammatory diseases, injuries in the eye, microbial infections such as viral, bacterial, and fungal infection or exposure to certain toxic chemicals such as strong acids or pesticides. However, in many cases the cause of this condition remains unknown. It is also found to be effecting people belonging to the age group of 20?50 years. The condition is classified based on the location of inflammation in the uvea and is categorized in three types including anterior uveitis that causes inflammation in the iris and is the most commonly encountered type. The other two types include intermediate uveitis and posterior uveitis that affects the posterior choroid part of the uvea. Uveitis can be treated with the help of various drugs that include corticosteroids, immunosuppressant, monoclonal antibodies, analgesics, and drug formulations.

To Access the Free Sample Report:

Market Dynamics

Major factors driving growth of the global uveitis treatment market include rising incidence of uveitis and complications associated with the disease. According to a survey published in research journal of JAMA Ophthalmology, non-infectious uveitis was reported in 121 cases per 100,000 adults and 29 per 100,000 children in 2016. Various other factors supporting the market growth include rising expenditure in research and development for new therapies to treat uveitis as well as speedy approvals from U.S. FDA for the drugs in pipeline to treat the condition. However, factors such as irreversible blindness in some cases due to side effects of medications and other such medical conditions can thus, hinder the market growth for global uveitis treatment. The side effects associated with corticosteroids include high blood pressure, kidney damage, skin disorders, and others.

Rise in development of innovative biologics is expected to accelerate growth of the market

Primary driving factor contributing towards growth of the uveitis treatment market is rising incidence of uveitis. According to a study by American University of Beirut Medical Center in 2015, Uveitis is responsible for 10% of legal blindness in the U.S. and up to 25% of blindness in the developing countries. Moreover, according to a study conducted by F. I. Proctor Foundation, University of California, San Francisco in 2013 suggested that uveitis incidence rate among the U.S. population could be approximated to 24.9 cases per 100,000 people. In addition to this, several other factors driving growth of the market include rise in healthcare expenditure for treatment development and development of new and innovative biologics for uveitis treatment. However, factors limiting growth of the market include side effects such as kidney damage, high blood sugar, and osteoporosis due to immunosuppressant drugs. Moreover, complications associated with the medication could result in irreversible blindness, which is a major factor limiting the market growth.

For More Details On this Report:

Speedy FDA approvals for uveitis treatment drugs to propel the market growth

A large number of new as well as established companies are focusing on development of drugs for the treatment of uveitis in various forms such as monoclonal antibodies, immunosuppressant, corticosteroids, anti-fungal agents, anti-viral agents, and others. FDA is focusing on speedy drug approval process as uveitis has serious ill effects leading to disorders such as glaucoma and permanent blindness. This creates a highly conducive environment for market players to invest in research and development activities to file for patents as well as develop generic biologics for treating this disorder. According to the Regulatory Affairs Professionals Society, FDA has approved around 38 generic drugs till July 2017.

Asia Pacific is expected to witness a significant growth in the global uveitis treatment market and this can be attributed to increasing number of regional players focusing on development of biologics for the treatment of uveitis. For instance, Santen Pharmaceuticals received U.S. FDA approval for its new drug in April 2017, for the treatment of non-infectious uveitis of the posterior segment.

Some of the major players operating in the uveitis treatment market are AbbVie, Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Santen Pharmaceuticals, Allergan Plc, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., and Alimera Sciences.

To Get Instant Access, Purchase Report Here:

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,


Seattle, WA 98154

Tel: +1-206-701-6702


Stock Symbols

Leave a Reply

Your email address will not be published. Required fields are marked *